Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review
Joshua De Soyza, Hung-Yeh Chien, Adeola Ayodotun Onasanya, Alice M Turner Institute of Applied Health Sciences, University of Birmingham, Birmingham, UKCorrespondence: Joshua De Soyza, Email j.desoyza@bham.ac.ukAbstract: Alpha-1 antitrypsin deficiency (AATD) is a rare cause of chronic lung and liver...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Patient Related Outcome Measures |
Subjects: | |
Online Access: | https://www.dovepress.com/is-it-time-alpha-1-antitrypsin-deficiency-had-a-specific-patient-repor-peer-reviewed-fulltext-article-PROM |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841526592474447872 |
---|---|
author | De Soyza J Chien HY Onasanya AA Turner AM |
author_facet | De Soyza J Chien HY Onasanya AA Turner AM |
author_sort | De Soyza J |
collection | DOAJ |
description | Joshua De Soyza, Hung-Yeh Chien, Adeola Ayodotun Onasanya, Alice M Turner Institute of Applied Health Sciences, University of Birmingham, Birmingham, UKCorrespondence: Joshua De Soyza, Email j.desoyza@bham.ac.ukAbstract: Alpha-1 antitrypsin deficiency (AATD) is a rare cause of chronic lung and liver disease without its own patient reported-outcome measure (PROM). PROMs for Chronic Obstructive Pulmonary Disease (COPD) are commonly used instead, but AATD differs from COPD in several ways. We reviewed whether the PROMs used in the AATD literature adequately assess quality-of-life in these patients. 11 studies used PROMs as their primary outcomes; 21 included them as secondary outcomes. The St George’s Respiratory Questionnaire (SGRQ) was the most commonly used PROM, used by 7 of the 11 primary outcome studies. Others included the COPD Assessment Tool, SF-36, LCOPD, EQ-5D, and the Chronic Respiratory Diseases Questionnaire. Several studies assessed SGRQ as being associated with respiratory disease severity as measured by FEV1% predicted, exacerbation rate, oxygen use and exercise tolerance. However, no studies used PROMs which included assessment of liver-related symptoms, other extra-pulmonary manifestations of AATD, or concerns related to genetics or finances. These factors are likely to have an impact on quality of life in AATD. A specific AATD-PROM is therefore required to holistically address the quality of life effects of an AATD diagnosis.Keywords: alpha-1 antitrypsin deficiency, COPD, chronic liver disease, rare diseases |
format | Article |
id | doaj-art-ad755f6aaaab4bc589cf009145caf850 |
institution | Kabale University |
issn | 1179-271X |
language | English |
publishDate | 2025-01-01 |
publisher | Dove Medical Press |
record_format | Article |
series | Patient Related Outcome Measures |
spelling | doaj-art-ad755f6aaaab4bc589cf009145caf8502025-01-16T16:17:13ZengDove Medical PressPatient Related Outcome Measures1179-271X2025-01-01Volume 16233599249Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A ReviewDe Soyza JChien HYOnasanya AATurner AMJoshua De Soyza, Hung-Yeh Chien, Adeola Ayodotun Onasanya, Alice M Turner Institute of Applied Health Sciences, University of Birmingham, Birmingham, UKCorrespondence: Joshua De Soyza, Email j.desoyza@bham.ac.ukAbstract: Alpha-1 antitrypsin deficiency (AATD) is a rare cause of chronic lung and liver disease without its own patient reported-outcome measure (PROM). PROMs for Chronic Obstructive Pulmonary Disease (COPD) are commonly used instead, but AATD differs from COPD in several ways. We reviewed whether the PROMs used in the AATD literature adequately assess quality-of-life in these patients. 11 studies used PROMs as their primary outcomes; 21 included them as secondary outcomes. The St George’s Respiratory Questionnaire (SGRQ) was the most commonly used PROM, used by 7 of the 11 primary outcome studies. Others included the COPD Assessment Tool, SF-36, LCOPD, EQ-5D, and the Chronic Respiratory Diseases Questionnaire. Several studies assessed SGRQ as being associated with respiratory disease severity as measured by FEV1% predicted, exacerbation rate, oxygen use and exercise tolerance. However, no studies used PROMs which included assessment of liver-related symptoms, other extra-pulmonary manifestations of AATD, or concerns related to genetics or finances. These factors are likely to have an impact on quality of life in AATD. A specific AATD-PROM is therefore required to holistically address the quality of life effects of an AATD diagnosis.Keywords: alpha-1 antitrypsin deficiency, COPD, chronic liver disease, rare diseaseshttps://www.dovepress.com/is-it-time-alpha-1-antitrypsin-deficiency-had-a-specific-patient-repor-peer-reviewed-fulltext-article-PROMalpha-1 antitrypsin deficiencycopdchronic liver diseaserare diseases |
spellingShingle | De Soyza J Chien HY Onasanya AA Turner AM Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review Patient Related Outcome Measures alpha-1 antitrypsin deficiency copd chronic liver disease rare diseases |
title | Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review |
title_full | Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review |
title_fullStr | Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review |
title_full_unstemmed | Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review |
title_short | Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review |
title_sort | is it time alpha 1 antitrypsin deficiency had a specific patient reported outcome measure a review |
topic | alpha-1 antitrypsin deficiency copd chronic liver disease rare diseases |
url | https://www.dovepress.com/is-it-time-alpha-1-antitrypsin-deficiency-had-a-specific-patient-repor-peer-reviewed-fulltext-article-PROM |
work_keys_str_mv | AT desoyzaj isittimealpha1antitrypsindeficiencyhadaspecificpatientreportedoutcomemeasureareview AT chienhy isittimealpha1antitrypsindeficiencyhadaspecificpatientreportedoutcomemeasureareview AT onasanyaaa isittimealpha1antitrypsindeficiencyhadaspecificpatientreportedoutcomemeasureareview AT turneram isittimealpha1antitrypsindeficiencyhadaspecificpatientreportedoutcomemeasureareview |